Century Therapeutics (IPSC) Non-Current Deferred Tax Liability (2022 - 2026)

Century Therapeutics (IPSC) has reported Non-Current Deferred Tax Liability for 4 consecutive years, with $4.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability fell 1.67% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (down 1.67% YoY), while the FY2025 annual figure was $4.3 million, down 1.67% from the prior year.
• Non-Current Deferred Tax Liability held at $4.3 million in Q1 2026 per IPSC's latest filing, from $4.3 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $4.4 million in Q4 2024 and bottomed at $5000.0 in Q4 2022.
• Historically, Non-Current Deferred Tax Liability has averaged $3.7 million across 4 years, with a median of $4.3 million in 2025.
• On a YoY basis, Non-Current Deferred Tax Liability climbed as much as 29.95% in 2025 and fell as far as 1.67% in 2025.
• Century Therapeutics' Non-Current Deferred Tax Liability stood at $5000.0 in 2022, then surged by 87380.0% to $4.4 million in 2024, then decreased by 1.67% to $4.3 million in 2025, then changed by 0.0% to $4.3 million in 2026.
• Business Quant data shows IPSC's Non-Current Deferred Tax Liability at $4.3 million in Q1 2026, $4.3 million in Q4 2025, and $4.4 million in Q3 2025.